Alnylam Pharmace. buy UBS Group AG
Start price
01.08.25
/
50%
€347.20
Target price
01.08.26
€481.91
Performance (%)
7.66%
Price
20:50
€373.80
Summary
This prediction is currently active. The BUY prediction by UBS_Group_AG shows slight gains of 7.66%. This prediction currently runs until 01.08.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 8.736% |
| iShares Core DAX® | 0.683% |
| iShares Nasdaq 100 | -1.457% |
| iShares Nikkei 225® | 0.931% |
| iShares S&P 500 | -2.022% |
Comments by UBS_Group_AG for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $403.00 to $550.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by UBS_Group_AG for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€228.00
28.06.24
28.06.24
€268.93
28.06.25
28.06.25
20.53%
29.06.25
29.06.25
